Michael Falster
@michaelfalster
Followers
108
Following
192
Media
4
Statuses
29
Associate Professor, Epidemiologist, Biostatistician & data science geek @ UNSW. Proud dog parent & Eurovision fan. All views my own
Joined May 2008
Great start to #ACPE2024 Tokyo with the education session on Database Pharmacoepidemiology. Thanks to all my fellow presenters! @MedIntelCRE @Juliana_OCosta
1
2
10
Over 1M Australians are living with T2DM, but it is heart and kidney disease that are the major causes of death and sickness. There are diabetes medicines available that can also protect their hearts and kidneys, and potentially save lives, but many are missing out. 🧵1/4
1
2
2
Just out! Our review on meds dispensing duration for #hypertension
#HypertensionTaskforce The impact of short vs long durations on health costs and outcomes is unknown. Evidence suggests 90-day dispensing could reduce costs and improve adherence https://t.co/y128X2vInf
3
10
34
Congratulations to @MedIntelCRE researchers on the first study published using the MedIntel Data Platform. They examined how use of highly effective diabetes medicines (SGLT2is and GLP-1RAs) varied across geographic areas of NSW https://t.co/oEBmpZQKIq 🧵1/4
1
5
9
Excited to see @MedIntelCRE investigator @lindajialinglin present at the @NSWCVRN Rising Stars Seminar Series soon. Registrations open!!
Register now for the first @NSWCVRN Rising Stars Seminar of the year at @georgeinstitute's new harbourside location in Barangaroo on Thu 14 March. Followed by networking refreshments. Register here: https://t.co/qBI5ImrzNA
0
2
7
A successful @NSWCVRN EMCR Consumer Engagement Masterclass at Uni of Wollongong Business School! Great job to all the working group members! Looking forward to the next meeting or engagement! Now waiting for the final 9th flight back to Melbourne!
0
2
12
Only a few places left: 2023 NSW CVRN CONSUMER ENGAGEMENT MASTERCLASS. 16 November 9am - 2pm, Lunch provided Register online:
forms.office.com
REGISTRATION NOW OPEN: 2023 NSW CVRN EMCR Masterclass. 16 November 9am - 2pm, Lunch provided Register online: https://t.co/izNoboiqx7
0
7
6
@UNSWMedicine Particularly interesting: our results are consistent with international studies, despite Australia having a universal healthcare system. We need further linkage of clinical data to truly understand this finding @equityhealthj @heartfoundation @NSWCVRN @cbdrh1 @MedIntelCRE
0
0
4
Why do private and public patients have different mortality rates following PCI? No evidence of differential complications. Are they just very different people, or are there issues in timely access? Questions raised in our new research @UNSWMedicine
link.springer.com
International Journal for Equity in Health - International evidence suggests patients receiving cardiac interventions experience differential outcomes by their insurance status. We investigated...
1
2
10
Congratulations Tamie on winning best presentation @ UNSW CVMM Symposium! Endocrinonoloy meets pharmacoepidemiology, ⬆️ SGLT2i & GLP-1RAs as add on therapy for T2D. Thrilled to be part of your work :) @UNSWMedicine @MedIntelCRE @Juliana_OCosta @lindajialinglin @SalPearson
1
3
14
REGISTRATION NOW OPEN: 2023 NSW CVRN EMCR Masterclass. 16 November 9am - 2pm, Lunch provided Register online: https://t.co/izNoboiqx7
0
12
15
Thrilled to present on the epidemiology of SGLT2i and GLP-1RAs at Australasian Diabetes Congress. Thanks for inviting me - we’ve got some great work ahead!! #ADC2023 @MedIntelCRE @UNSWMedicine @SalPearson @Juliana_OCosta @lindajialinglin
0
3
13
Low persistence to 4 groups of cardiovascular medicines in 3 years, but high adherence while people are on therapy. Cardiovascular multi-medicine use is common (>31%) but does not appear to impair persistence and adherence to therapy. https://t.co/b0DtespD1m
@MedIntelCRE
0
6
11
“Continuous comparative assessments are needed to guide evidence for treatment decisions across the range of available devices” - @michaelfalster, @RamonVarcoeMD & colleagues #endograft #endovascular #aneurysm #EVAR
https://t.co/wfaMi3a1eM
vascularspecialistonline.com
A recent study comparing outcomes of endovascular aneurysm repair (EVAR) patients has reported no statistically significant differences in mortality or secondary rupture rates between standard Cook,...
0
1
1
ICYMI, our recent study on the comparative effectiveness of smoking cessation pharmacotherapies for secondary prevention of cardiovascular disease @clara_chow @KB_Filion @SalPearson @michaelfalster
Comparative effect of varenicline and nicotine 🚬 patches on preventing repeat cardiovascular events https://t.co/9A5VJWp9MZ
0
4
6
Please join us at 2pm on Tuesday 21st March to hear from our special guest @prieto_alhambra - "Data stays local - evidence goes global" and what Australia can learn from the DARWIN-EU project. Register https://t.co/uh46gjm4Hu to attend. @AusOHDSI @cbdrh1 @UNSWMedicine
0
4
8
For people who want to quit smoking, is varenicline better at reducing repeat heart attacks than nicotine patches? Our study on this question just published: https://t.co/d8DcpfBMRK
@michaelfalster @KB_Filion @clara_chow @NDARCNEWS @MedIntelCRE @Heart_BMJ
0
3
9
Can real-world data address an evidence gap where there are zero RCTs available? So proud of our paper comparing outcomes of different endograft devices for AAA repair. Editors choice! @cbdrh1 @MedIntelCRE
0
3
12
Great day today! Paper by @anschaf on multi-medicine use in patients with CVD is out. Not surprisingly it’s very common, check out the visualisations breaking down the combinations used. Also had my 50th paper accepted - celebrate the wins! @MedIntelCRE
0
1
9